AMH changes to predict ovarian function in perimenopausal breast cancer
Part of Cancer, Skin clinical trials.
This trial looks at how a hormone called AMH changes over time in women aged 45-55 with hormone receptor-positive breast cancer who are starting chemotherapy or hormone therapy. The goal is to see if AMH levels can help predict how well their ovaries are still working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 45 and 55 years old.
- You have been diagnosed with hormone receptor-positive breast cancer.
- You are perimenopausal, meaning your last period was within the last 3 months and certain hormone levels are in a specific range.
- You are about to start chemotherapy or hormone therapy after surgery.
- You are willing to have extra blood tests and keep a diary of your periods.
- You have not had both ovaries removed, pelvic radiation, or used certain hormone treatments recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures blood biomarkers to understand how breast cancer treatment affects a person’s future fertility (ovarian reserve). It may help patients learn more about egg supply changes after chemotherapy and hormone-related treatments.
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
This study tests whether switching the type of ovarian-suppressing medication helps keep hormone-sensitive breast cancer under control in younger women. You'll be screened to see if your current treatment is working, then potentially switched to a different formulation to see if it works better.
This study is looking for genetic markers that may help predict how chemotherapy affects the ovaries. It's for women who had breast cancer or lymphoma, froze their ovarian tissue before treatment, and finished that treatment at least 6 months ago.
This study looks at how genetic tests like Oncotype DX or Mammaprint are used to guide treatment decisions for people with early-stage, hormone receptor-positive (HR+) and HER2-negative breast cancer. It aims to help doctors choose between hormone therapy alone or chemotherapy plus hormone therapy.
This study looks at how a blood test called AMH (anti-Müllerian hormone) is used in people being seen for PCOS or POI (early ovarian failure). The goal is to understand whether AMH measurements are useful for care in clinics and fertility treatment settings.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.